Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


July 5th, 2022

Imugene Releases Final Survival Data in Phase II Gastric Cancer Study

Imugene (IMU: $0.225) has released final overall survival data from its Phase Ib/II HER-Vaxx study in 36 patients with advanced gastric cancer with tumours that overexpressed the HER2 receptor.

June 17th, 2022

Radiopharm Theranostics In-licenses Sixth Technology Program

Radiopharm Theranostics (RAD: $0.16) has in-licensed an additional targeting agent from Case Western Reserve University (CWRU) in the US.

The peptide licensed targets a fragment of a receptor found only on tumour cells and not in healthy tissue, called PTPµ. The peptide has been found, in preclinical studies, to recognise not only the main tumour but also small tumour metastases.

June 17th, 2022

Imricor Medical Systems – Pioneering MRI Assisted Cardiac Ablation

Imricor Medical Systems (IMR: $0.115) listed on the ASX in 2019 at $0.83 per share raising $13 million. The company was formed in 2006 in the US and is pioneering cardiac ablation treated specifically through the guidance of MRI. Traditional ablation procedures are conducted using fluoroscopy and x-ray imaging.

There are multiple advantages in using MRI to help guide the procedure, most notably the better imaging quality that can be achieved compared to x-ray. This results in arguably better ablation outcomes, less repeat procedures and shorter treatment periods. Efficacy of the ablation procedures involves inserting an ablation catheter through the veins or arteries to correct irregular electrical signals in the heart. Other safety benefits for patients and surgeons come from not using x-ray images.

June 17th, 2022

More Important Data for Patrys

Antibody development company Patrys (PAB: $0.021) has announced the publication of some new and important data around its rare portfolio of compounds.

June 3rd, 2022

Radiopharm Theranostics - Six Therapeutic Studies to Commence in 2023

CEO of Radiopharm Theranostics (RAD: $0.185), Riccardo Canevari, believes that the next big platform in oncology, following immunotherapy and cell therapies, will be radiopharmaceuticals.

Canevari highlighted the said the approval of Lutathera (in 2018) from Novartis (where Canevari was working at the time), for the treatment of neuroendocrine tumours and the more recent approval this year of Pluvicto (also from Novartis) as key events for the sector. Lutathera achieved a stunning efficacy result in its pivotal trial achieving a hazard ratio of 0.21, meaning a 79% risk reductio of disease progression or death. For Pluvicto, reaching primary and secondary endpoints in prostate cancer was a game changer.

June 3rd, 2022

Patrys - Can Its Antibodies Prevent Metastases?

By 2027 the sales of biologics are predicted to surpass the aggregate sales of small molecule drugs, with US$120 billion more sales and making up 55% of all drug sales. This is a positive aspect for Patrys (PAB: $0.022), an antibody therapeutics company, according to CEO James Campbell. However, small molecule drug sales are still expected to increase by around 50% over this period driven by CNS therapy product sales.

June 3rd, 2022

Dimerix - Structural Regulatory Changes in Kidney Diseases Perfect Timing

During the pandemic, Dimerix (DXB: $0.17) was very pleased to have been able to complete two Phase II kidney disease studies. The company has now moved to a Phase III program in FSGS (kidney disease) involving 75 sites spread across 12 countries, including in the US where the company recently gained FDA approval (IND) to commence its study there as well. The first patient was treated in this study this week.

Dimerix CEO Nina Webster said that sclerotic kidney disease is a progressive three mechanism cycle that results in an acceleration of the disease as it progresses to end stage kidney failure. The drugs currently on the market all focus on the first mechanism of this disease by reducing hypertension across the bloodstream.

May 25th, 2022

Chimeric Antigen Receptor T Cell Therapies

CAR-T therapies currently remain predominantly for use in oncology according to Chimeric Therapeutics CEO and Bioshares Biotech Summit keynote speaker Jennifer Chow.

Cancer therapies commenced largely in the 1940's with chemotherapy, which could be described as bombing the patient with broad acting drugs. This was followed by targeted therapies in the 1990's such as monoclonal antibodies. In the last decade, the major advances have been in immunotherapies, such as checkpoint therapies. These targeted therapies started to improve short-term survival, and then the immunotherapies were found to improve long-term survival.

May 25th, 2022

Bioshares Biotech Summit Conference Coverage - Cogstate

During the pandemic, Cogstate CEO Brad O'Connor said the whole pharmaceutical industry saw the demand for remote assessments in clinical trials increase, with the company's digital cognitive assessments well set up for decentralized studies.

May 3rd, 2022

Cogstate Reports Record - Sales Up 105%

Cognitive assessment company Cogstate has signed US$73.6 million of new sales contracts, up 105% on the PCP. This is a record for the company.